Targeted treprostinil delivery inhibits pulmonary arterial remodeling.
Sign Up to like & getrecommendations! Published in 2022 at "European journal of pharmacology"
DOI: 10.1016/j.ejphar.2021.174700
Abstract: INTRODUCTION Pulmonary arterial hypertension (PAH) is a fatal disease caused by the progressive remodeling of pulmonary arteries (PAs). Treprostinil (TPS) is a tricyclic benzidine prostacyclin clinically used for PAH treatment. However, due to low bioavailability,… read more here.
Keywords: delivery; pah; modified liposomes; tps ... See more keywords